Ottawa COPD Risk Scale
Estimates the risk of a short-term serious adverse event (death, intubation, admission to a monitored unit, or return to the ED needing admission) in ED patients with an exacerbation of COPD. The authors suggest admission at a score of 2 or more.
Score interpretation
Score 0: serious adverse event risk 2.2% (Stiell 2014).
→ Discharge may be considered with close follow-up, adequate medication supply and education.
Score 1: serious adverse event risk 4.0% (Stiell 2014).
→ Reassess after ED treatment; discharge only with early follow-up and a safety-net plan.
Score ≥ 2: serious adverse event risk 7.2% or more, rising to 91.4% at a score of 10 (Stiell 2014).
→ Admission suggested by the authors at a score of 2 or more; senior review, consider HDU / NIV if indicated.
Interpretation bands for the Ottawa COPD. Apply clinical judgement and local guidance.
References
- Stiell IG, et al. Clinical characteristics associated with adverse events in patients with exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. CMAJ. 2014;186(6):E193–E204.
Related
Curated clinical cross-links plus same-class fallbacks.
- Azithromycin (COPD Exacerbation Prophylaxis) · Macrolide antibiotic (anti-inflammatory / prophylactic)
- Doxycycline (COPD Exacerbation / CAP) · Oral tetracycline antibiotic
- Co-amoxiclav 625mg (COPD Exacerbation / CAP) · Beta-lactam / Beta-lactamase inhibitor combination antibiotic
- Labetalol (IV — Hypertensive Emergency) · Combined Alpha-1 and Beta-Adrenergic Blocker
- Labetalol (IV — Hypertensive Emergency) · Combined alpha and beta blocker
- Tenecteplase · Cardiovascular Emergency
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.